Search Results
Your search for ,kEY matches 7151 pages
Showing 1751 - 1800Adding Tiragolumab to Atezolizumab and Chemotherapy in Previously Untreated Extensive-Stage SCLC
As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...
Predicting Primary Ovarian Insufficiency in Childhood Cancer Survivors
As reported in The Lancet Oncology, Im et al have developed risk-prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer. Study Details In the study, models to predict age-specific risk of primary ovarian insufficiency were evaluated among 5-year survivors...
Colorectal Cancer: Incidence and Time to Recurrence
In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal cancer decreased over time and the time to recurrence was shorter with a more advanced disease stage. Study Details The study used the Danish...
Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors
In a European study reported in the Journal of Clinical Oncology, Heymer et al found that the risk of subsequent colorectal cancer was elevated among childhood cancer survivors who had undergone abdominopelvic radiotherapy. Study Details The study used data from the PanCareSurFup Study—a...
Highlights From the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid reported out several eagerly awaited and potentially practice-changing trials, bringing forward promising new combination strategies in the targeted and immunotherapy space, and put to the test selective agents against...
CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer
The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...
Expert Point of View: Andrea Apolo, MD
Invited discussant Andrea Apolo, MD, of the National Cancer Institute in Bethesda, Maryland, emphasized that the EV-302/KEYNOTE-A39 and CheckMate 901 trials mark a significant achievement. “Outperforming chemotherapy in first-line therapy is monumental for our field. The two studies presented are...
First-Line Selpercatinib: New Standard of Care for RET-Positive Medullary Thyroid Cancer?
First-line treatment with selpercatinib achieved a statistically significant improvement in progression-free survival and overall response rate vs treatment with cabozantinib or vandetanib in patients with multikinase inhibitor–naive, RET-mutant advanced or metastatic medullary thyroid cancer.1 At...
Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL
In a German phase II trial (INITIAL-1) reported in the Journal of Clinical Oncology, Matthias Stelljes, MD, and colleagues found that inotuzumab ozogamicin–based induction therapy followed by age-adapted chemotherapy was associated with promising outcomes in newly diagnosed patients older than age...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Trastuzumab Plus Gemcitabine/Cisplatin in Advanced HER2-Positive Biliary Tract Adenocarcinoma
In an Indian phase II trial reported in the Journal of Clinical Oncology, Ostwal et al found that trastuzumab plus gemcitabine/cisplatin was active in treatment-naive patients with advanced HER2-positive biliary tract adenocarcinoma. Study Details In the investigator-initiated multicenter trial, 90 ...
Incidence of Breast Cancer After False-Positive Mammography
In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently diagnosed with breast cancer compared to women with no false-positive result. Study Details The study involved data from 45,213 women who received a...
ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
Adding Atezolizumab to Perioperative Chemotherapy in Resectable Esophagogastric Cancer
As reported in the Journal of Clinical Oncology by Lorenzen et al, the phase II portion of the German-Swiss phase II/III DANTE/IKF-s633 trial showed promising results with the addition of atezolizumab to perioperative chemotherapy in patients with resectable esophagogastric cancer. Study Details In ...
Novel Uterine Cancer Detection Method for Women With Abnormal Uterine Bleeding
In a UK single-institution study (EPI-SURE) reported in The Lancet Oncology, Evans et al found that the novel WID-qEC DNA methylation test outperformed ultrasonography in detecting uterine cancer in women with abnormal uterine bleeding. Study Details The prospective observational study invited...
Outcomes With Olaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer in the PROfound Trial
In an analysis of the phase III PROfound trial reported in the Journal of Clinical Oncology, Joaquin Mateo, MD, PhD, and colleagues found that olaparib improved outcomes vs abiraterone or enzalutamide among the subgroup of patients with metastatic castration-resistant prostate cancer who had...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Expert Point of View: Paula Antonia Ugalde, MD
Discussant of the abstract on the MARS-2 trial, Paula Antonia Ugalde, MD, Associate Surgeon, Division of Thoracic Surgery, Brigham and Women’s Hospital, Boston, underscored the significance of this “outstanding trial,” which she called a “landmark study for the field.” Despite the ban on asbestos, ...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 100 members during its annual meeting, including 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated major...
Society for Integrative Oncology Celebrates 20 Years of Excellence
Guest Editor’s Note: The Society for Integrative Oncology (SIO) held its 20th international conference in Banff, Alberta, Canada. The conference focused on the theme “Integrative Oncology as Standard of Care: The Time Is Now.” The mood was festive, and the weather cooperated with warm temperatures, ...
From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...
Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data
Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies,1 Rebecca Olin, MD, MSCE, of UCSF Helen Diller Family...
Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023
Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated...
Metastatic Castration-Resistant Prostate Cancer: Efficacy of Anti-PSMA Antibody With Alpha Emitter
In a phase I study reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, FASCO, FACP, and colleagues determined the recommended phase II dose and described preliminary activity of actinium-225–J591—an anti–prostate-specific membrane antigen (PSMA) monoclonal antibody (J591)...
Early-Stage Cervical Cancer: Defining Follow-up After Fertility-Sparing Surgery
In a Dutch retrospective cohort study reported in The Lancet Oncology, Schuurman et al identified follow-up strategies based on cytology and human papillomavirus (HPV) testing after fertility-sparing surgery for early-stage cervical cancer. Study Details The nationwide population-based study used...
Axillary Soft-Tissue Involvement in Lymph Node–Positive Breast Cancer
In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Naoum et al found that pathologic exploration of axillary soft tissue in patients with lymph node–positive breast cancer is a critical element in predicting disease outcome and in determining axillary...
Blinatumomab as an Alternative to First-Line Intensive Chemotherapy in Pediatric B-Cell ALL
In a retrospective study reported in the Journal of Clinical Oncology, Hodder et al found that blinatumomab was effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons with B-cell acute lymphoblastic leukemia (ALL) who were...
PROpel Trial: Olaparib Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer Unselected for HRR Mutation Status
As reported in The Lancet Oncology by Fred Saad, MD, of the Centre Hospitalier de l’Université de Montréal, and colleagues, the final prespecified overall survival analysis of the phase III PROpel trial has shown no significant benefit with the addition of first-line olaparib to abiraterone in...
Survivors of Childhood Cancer: Study Shows Heart-Related Ailments Linked to Radiotherapy Dose
Research on the advances in radiation modeling presented by Rebecca M. Howell, PhD, at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting may provide insights into the late cardiac effects of survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS).1 Dr....
Perioperative Durvalumab Improves Surgical Outcomes in Resectable NSCLC: Phase III AEGEAN Trial
The addition of durvalumab to neoadjuvant chemotherapy led to higher rates of R0 resections and posed no apparent impediments to successful surgery for resectable non–small cell lung cancer (NSCLC), according to findings from the randomized phase III AEGEAN trial presented at the International...
In Recurrent Cervical Cancer, Tisotumab Vedotin-tftv Improves Overall Survival in Phase III Trial
In the global randomized open-label phase III innovaTV 301/ENGOT-cx12/GOG-3057 trial, treatment with the antibody-drug conjugate tisotumab vedotin-tftv resulted in a statistically significant 30% reduction in the risk of death in patients previously treated for recurrent or metastatic cervical...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
Overall Survival With CTC Count–Driven Treatment in Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the French phase III STIC CTC trial showed a nonsignificant overall survival benefit with a circulating tumor cell (CTC) count–driven approach to therapy vs physician’s choice in the first-line...
Addition of Adjuvant HIPEC to Standard Chemotherapy in Locally Advanced Colon Cancer
As reported in the Journal of Clinical Oncology by Zwanenburg et al, 5-year findings from the Dutch COLOPEC trial indicated that the addition of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) to systemic chemotherapy did not improve overall survival vs chemotherapy alone in patients...
FDA Approves Capivasertib With Fulvestrant for Breast Cancer
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an...
FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC
On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...
Modified vs Standard Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma
In a UK phase II trial (PRISM) reported in the Journal of Clinical Oncology, Vasudev and colleagues found that ipilimumab given every 12 weeks vs every 3 weeks in combination with nivolumab resulted in a significantly reduced rate of treatment-related grade ≥ 3 adverse events in treatment-naive...
Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia: GLOW Trial 4-Year Follow-up
As reported in The Lancet Oncology by Niemann et al, the 4-year follow-up of the phase III GLOW trial has shown a continued progression-free survival benefit with fixed-duration ibrutinib/venetoclax vs chlorambucil/obinutuzumab in the first-line treatment of chronic lymphocytic leukemia in patients ...
Expert Point of View: Andrea Apolo, MD
Invited discussant Andrea Apolo, MD, of the National Cancer Institute in Bethesda, Maryland, emphasized that the EV-302/KEYNOTE-A39 and CheckMate 901 trials mark a significant achievement. “Outperforming chemotherapy in first-line therapy is monumental for our field. The two studies presented are...
Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States
In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care. As stated by the investigators: “Young individuals racialized as Black...
Ofranergene Obadenovec With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer
In a phase III trial (OVAL Study/GOG 3018) reported in the Journal of Clinical Oncology, Arend et al found that the addition of ofranergene obadenovec to paclitaxel did not improve survival outcomes in patients with platinum-resistant ovarian cancer. Ofranergene obadenovec is a gene-based targeted...
AI-Based Pathology for Assessing Sensitivity to Atezolizumab/Bevacizumab in HCC
As reported in The Lancet Oncology, Zeng et al developed an artificial intelligence (AI)-based pathology method that distinguished between better and poorer response to treatment with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC). As stated by the investigators:...
Long-Term Organ Preservation With Total Neoadjuvant Therapy in Rectal Adenocarcinoma
In a 5-year follow-up of the phase II OPRA trial reported in the Journal of Clinical Oncology, Verheij et al found that many patients receiving total neoadjuvant therapy for rectal adenocarcinoma remained free of the need for total mesorectal excision. Study Details In the U.S. multicenter trial,...
Effect of Bendamustine Prior to Apheresis on Outcomes in Large B-Cell Lymphoma Treated With CAR T-Cell Therapy
In a retrospective study reported in the Journal of Clinical Oncology, Iacoboni et al found that preapheresis bendamustine exposure was associated with poorer outcomes among patients with relapsed or refractory large B-cell lymphoma receiving CD19-targeted chimeric antigen receptor (CAR) T-cell...
Understanding Patient Engagement in Virtual Mind-Body Therapies
Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...
Subsequent Cancer Diagnosis After No Diagnosis With Urgent Suspected Cancer Referral
In a national cohort study in England reported in The Lancet Oncology, Scott et al found a high rate of subsequent cancer diagnosis in persons with an urgent suspected cancer referral that did not result in cancer diagnosis. As noted by the investigators, “Following referral for investigation of...
Metastatic Castration-Resistant Prostate Cancer: Single-Dose LuPSMA Plus Maintenance Pembrolizumab
In a single-institution phase I dose-expansion trial reported in The Lancet Oncology, Aggarwal et al found that a single dose of lutetium-177–PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. Study...
Adding Pembrolizumab to Trastuzumab and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: KEYNOTE-811
In interim analyses from the phase III KEYNOTE-811 trial reported in The Lancet, Yelena Y. Janjigian, MD, and colleagues found that the addition of pembrolizumab to trastuzumab and chemotherapy in first-line treatment of patients with locally advanced or metastatic HER2-positive...
Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Adjuvant Atezolizumab/Bevacizumab vs Active Surveillance in Resected or Ablated High-Risk Hepatocellular Carcinoma
As reported in The Lancet by Shukui Qin, MD, and colleagues, interim analysis of the phase III IMbrave050 trial has shown significantly better recurrence-free survival with adjuvant atezolizumab/bevacizumab vs active surveillance in patients who underwent curative-intent resection or ablation for...
